Business Article

ANDA Approval for Sunitinib

We are pleased to announce that we recently received Abbreviated New Drug Application (ANDA) approval for Sunitinib 12.5mg, 25mg, 37.5mg & 50mg by U.S. Food and Drug Administration (U.S. FDA).

This accreditation by U.S. FDA regulatory agency marked another notable achievement for Novugen after the previous ANDA Approval for Abiraterone.

The milestone denotes Novugen's growth as we thrive to becoming a competitive player in the U.S. pharmaceutical market adding another ANDA to our portfolio.

This demonstrates strong dedication from the people behind Novugen to serve patients in every corner of the world with the highest quality standard of niche and highly technical generics.

#ANDAApproval #Sunitinib #Oncology #AcceleratingAffordableMedicine #Novugen